News

Article

Pharmaceutical Technology

Pharmaceutical Technology-11-02-2004
Volume28
Issue 11

Searching for a Viable Business Model

Author(s):

Jim Miller

What should pharmaceutical companies make of recent corporate developments at several high-profile service providers?

External Link - article-132385.pdf

Articles in this issue
Still Waiting for Answers
Method Validation by Phase of Development: An Acceptable Analytical Practice
Comparing and Contrasting Barrier Isolator Decontamination Systems
November 2004
In the Spotlight-November 2004
Searching for a Viable Business Model

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results
August 23rd 2025

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Christopher Cole
Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends
August 23rd 2025

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Felicity Thomas
Creative digital data transfer and exchange folders on dark wallpaper. Backup data, virtual document storage or loading on cloud service. 3D Rendering | © Who is Danny - stock.adobe.com
August 23rd 2025

Emerging Tools, Integrated Controls Impact Tech Transfer

Patrick Lavery
Drug Solutions Podcast: Examining the State of Biopharma Investment
August 23rd 2025

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
August 23rd 2025

ESTEVE CDMO Acquires Regis Technologies

Susan Haigney
Survey with blurred city abstract lights background | Image Credit: © Tierney - stock.adobe.com
August 23rd 2025

Survey: Impacts of Tariffs and Trade Policy on the Bio/pharmaceutical Industry

Christopher Cole